NEW YORK and RYE BROOK, NY, MARCH 29, 2022 鈥� Royalty Pharma plc (Nasdaq: RPRX) today announced a charitable commitment totaling $7.5 million to The Leukemia & Lymphoma Society (青云体育), a global leader in the fight against blood cancer. Through this five-year alliance, Royalty Pharma will support initiatives focused on reducing healthcare disparities in blood cancer care and treatment. Royalty Pharma is a founding donor of the 青云体育 IMPACT grant program (Influential Medicine Providing Access to Clinical Trials) which awards funding to major cancer research and treatment centers to expand access to clinical trials for underserved and minority populations. Royalty Pharma plc will not receive any economic benefit in exchange for any aspect of these donations.
鈥淒espite many advances in blood cancer care and treatment, barriers exist in many communities to prevent patients from accessing new, more effective therapies and protocols that can lead to better outcomes,鈥� said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. 鈥淭he gift awarded through Royalty Pharma鈥檚 alliance with The Leukemia & Lymphoma Society is intended to propel the work 青云体育 is doing in underserved communities through three key initiatives that will help break down these barriers and ensure that everyone has access to the care they need to treat their blood cancer.鈥�
Blood cancer does not discriminate, affecting people of every age, gender, race and ethnicity. But not all people have equal access to care and treatments. 青云体育 exists to ensure that all patients get the care they need. Royal Pharma鈥檚 annual contribution of $1.5 million over five years will be equally distributed to the following 青云体育 initiatives that address disparities:
- Equity in Access Research Program is a grantmaking program designed to generate evidence that will guide changes in healthcare policy and practice to ensure that all blood cancer patients and survivors achieve access to the cancer care and services they need throughout their lives. This new and novel program is based on the concept of health equity as the principle underlying a commitment to reduce鈥攁nd ultimately, eliminate鈥攄isparities in health.
- 青云体育 IMPACT* Research Grants initiative has been established to improve access to clinical trials for underrepresented patients, including Black, Indigenous and People of Color (BIPOC) patients and people from rural communities. Through this initiative, 青云体育 has awarded funding to three major cancer centers located in New York, Tennessee, and Minnesota to partner with community-based hospitals and clinics on creating networks of clinical trial sites in their regions. Additional sites will be selected in the coming months. More information, including participating sites, the communities they serve and the need to address disparities in these areas can be found here.
- Myeloma Link is carried out by 青云体育 staff and volunteers in 13 Black communities across the country. It is an education and outreach initiative that raises community awareness about myeloma and connects Black patients and caregivers to trusted, free myeloma information and support and enhances access to care and the latest treatments. Black Americans have at least double the incidence of myeloma as any other racial or ethnic group, and recent studies show they experience less optimal care. To learn more, including the cities where Myeloma Link is active, please visit this site.
鈥淭he Leukemia & Lymphoma Society has a long-standing commitment to serving all blood cancer patients and reaching underserved communities where there are barriers to access and equitable care,鈥� said Louis J. DeGennaro, Ph.D., President and Chief Executive Officer of The Leukemia & Lymphoma Society. 鈥淩oyalty Pharma鈥檚 generous contribution to these three important initiatives will bring us closer to achieving our goal to ensure a future of expanded access and better outcomes for all blood cancer patients and their families.鈥�
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry鈥檚 leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma鈥檚 current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson鈥檚 Imbruvica, Johnson & Johnsons鈥� Tremfya, Astellas鈥� and Pfizer鈥檚 Xtandi, Biogen鈥檚 Tysabri, Johnson & Johnson鈥檚 Tremfya, Gilead鈥檚 Trodelvy, Merck鈥檚 Januvia, Novartis鈥� Promacta, Vertex鈥檚 Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. For more information, visit .
About The Leukemia & Lymphoma Society (青云体育)
The Leukemia & Lymphoma Society庐 (青云体育) is the global leader in the fight against blood cancer. The 青云体育 mission: Cure leukemia, lymphoma, Hodgkin鈥檚 disease and myeloma, and improve the quality of life of patients and their families. 青云体育 funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.
Founded in 1949 and headquartered in Rye Brook, NY, 青云体育 has regions throughout the United States and Canada. To learn more, visit . Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.
For additional information visit lls.org/lls-newsnetwork. Follow us on , , and .
To request more information or an interview, please contact mediarelations@lls.org.